AI helps a multidisciplinary team decide NSCLC treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial compares treatment recommendations from a conventional multidisciplinary team with those generated by a locally deployed AI model, and then examines how clinicians adjust their final plan after seeing the AI output. It uses patients’ clinical, imaging, and molecular data to produce independent recommendations from the MDT and the AI, with a final clinician-determined treatment plan after AI review. The study aims to measure agreement, decision modification rates, and efficiency of decision-making in NSCLC care. It does not specify a randomized design or phase, focusing on assessment of concordance and safety in real-world MDT workflows.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years;
2. MDT (Multidisciplinary Team) discussion deems a systemic treatment plan necessary;
3. Complete clinical, imaging, and molecular pathological data.

Exclusion Criteria:

1. Stage I patients;
2. Diagnosed with a thoracic tumor other than NSCLC;
3. Lack of detailed medical data, or missing data;

Where it's running

• Guangdong Provincial People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: qing liang, Dr.
• Email: liangtsing99@163.com
• Phone: +86 17863321987

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Evaluating DZD6008 for advanced lung cancer with EGFR mutations

  This study is testing a new oral medication called DZD6008 to see if it can safely help people with advanced lung cancer who have specific EGFR mutations.

  Recruiting Phase 1 Dizal Pharmaceuticals · Beijing, Beijing Municipality · NCT06813365

• Testing HS-10365 for advanced lung cancer with RET gene fusion

  This study is testing a new pill called HS-10365 to see if it helps people with advanced lung cancer that has a specific gene change and who haven't had treatment before.

  Recruiting Phase 2 Jiangsu Hansoh Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06147570

• Evaluating the safety of a new treatment for certain cancer types

  This study is testing a new treatment for certain types of cancer to see if it's safe for adults with recurrent or metastatic tumors.

  Recruiting at 4 sites Phase 1 Orano Med LLC · Chicago, Illinois and 7 other locations · NCT05283330

• Supportive care model for patients with advanced lung cancer

  This study is testing a new supportive care program for people with advanced lung cancer to see if it helps them feel less stressed and more confident about managing their condition compared to standard care.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT04900935

• Comparing treatment outcomes in lung cancer patients with different performance statuses

  This study is testing if immunotherapy treatments can help lung cancer patients with lower performance status feel better and live longer compared to those with better performance status.

  Recruiting at 2 sites Phase 2 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT04253964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.